X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to accelerate Phase 3 development of Qtorin™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
Lead Product(s): Sirolimus
Therapeutic Area: Rare Diseases and Disorders Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Partnership December 01, 2023
Details:
Qtorin (rapamycin) is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus. It is being evaluated for the treatment of microcystic lymphatic malformations.
Lead Product(s): Sirolimus
Therapeutic Area: Rare Diseases and Disorders Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
Qtorin (rapamycin) a topical mTOR inhibitor, which is being investigated for the treatment of microcystic lymphatic malformations and in individuals with basal cell carcinomas (BCCs) in gorlin syndrome (GS).
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Qtorin (rapamycin), a topical mTOR inhibitor and the lead product candidate from the QTORIN™ platform, is being investigated in Phase 3 clinical trial for the treatment of Pachyonychia Congenita (PC).
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: Qtorin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Qtorin™ (rapamycin) is the lead product candidate from Palvella’s QTORIN™ platform and is initially under evaluation for for the treatment of individuals with Pachyonychia Congenita and Microcystic LM, as well as for the prevention of BCCs in individuals with GS.
Lead Product(s): Sirolimus
Therapeutic Area: Rare Diseases and Disorders Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Qtorin™ (rapamycin) is the lead product candidate from Palvella’s QTORIN™ platform and is initially under evaluation for for the treatment of individuals with Pachyonychia Congenita and Microcystic LM, as well as for the prevention of BCCs in individuals with GS.
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: Qtorin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Proceeds from the financing will be used to advance the development QTORIN rapamycin anhydrous gel for the treatment of Pachyonychia Congenita, treatment of Microcystic Lymphatic Malformations, and for the prevention of Basal Cell Carcinomas in Gorlin Syndrome.
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: QTORIN
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Petrichor
Deal Size: $37.7 million Upfront Cash: Undisclosed
Deal Type: Series D Financing January 05, 2023
Details:
The milestone payment comes as a result of a development funding and royalties agreement to advance their lead product candidate PTX-022 (QTORIN™ 3.9% rapamycin anhydrous gel) for the treatment of pachyonychia congenita.
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Ligand Pharmaceuticals
Deal Size: $3.0 milion Upfront Cash: $2.0 milion
Deal Type: Agreement May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
